

FOI - 8194 Treatment for Myelofibrosis		
Questions	Notes/Comments	Response
Q1. Does your trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?	Pharmacy or Information teams are unable to answer this question.	N/A
Q2. Please provide the total number of patients treated in the last 6 months for: • Polycythaemia Vera (ICD10 code D45) • Myelofibrosis (ICD10 code D47.4) • Myelofibrosis (ICD10 code D47.4) patients aged 65 and older	Counted are all patients diagnosed with the ICD10 codes D45, D47.4 between 1st December 2022 and 31st May 2023 the last complete 6 months of data available.	 Polycythaemia Vera (ICD10 code D45X): 39 Myelofibrosis (ICD10 code D47.4): 42 Myelofibrosis (ICD10 code D47.4) patients aged 65 and older: 20
Q3. How many patients were treated in the past 6 months (for any disease) with: • Ruxolitinib • Fedratinib	Counted are all patients treated with Ruxolitinib between 1st December 2022 and 31st May 2023. This data was provided by Pharmacy.	Ruxolitinib: 7 patients Fedratinib: 0 patients
Q4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for: • Polycythaemia Vera (ICD10 code D45X) • Myelofibrosis (ICD10 code D47.4)	Counted are all patients treated with Ruxolitinib and diagnosed with the coded conditions between 1st December 2022 and 31st May 2023 the last complete 6 months of data available.	1 patient diagnosed with Myelofibrosis
Q5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? • Of these patients, how many were treated in the past 6 months with Hydroxycarbamide? • Of these patients, how many were treated in the past 6 months with Interferon therapy? • Of these patients, how many have received no active treatment in the past 6 months?	Counted are all the patients diagnosed with ICD10 code D47.4 between 1st June 2020 and 31st May 2023 The number of treated patients was provided by pharmacy based on the MRN's provided by Information.	Hydroxycarbamide: 3 patients Interferon therapy: 1 patient No active treatment: 20 patients
Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.	The answer to this question was provided by the pharmacy team.	MKUH does not participate in any trial for treatment of Myelofibrosis